BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced the launch of BD Microtainer® MAP Microtube for Automated Process for hematology testing.
The new product is designed to improve the safety, accuracy and turnaround time of capillary blood collection and testing in patients with veins that can be difficult to access, such as infants, children, oncology patients and the elderly. The new BD Microtainer MAP product is also the first microtube to be fully compatible with most automated hematology instruments, reducing turnaround time and costs associated with sample transfer and relabeling.
“Clinical laboratories are focused on preventing specimen identification errors that can lead to misdiagnosis of patients. We at BD are pleased to introduce the BD Microtainer MAP product to address this healthcare issue. BD is committed to continuing our history of innovation in helping improve patient safety and healthcare worker safety, while enhancing workflow efficiency.” said Tom Polen, President, BD Diagnostics – Preanalytical Systems.
The BD Microtainer MAP tube is the first low-volume collection system to accommodate standard, full-size patient identification labels, thus reducing the risk of labeling errors. This feature offers a significant improvement over traditional microcollection tubes, which are incompatible with standard labels due to their size. This disparity can lead to dangerous labeling errors that may result in misdiagnosis and incorrect patient treatment.
The innovative design of the BD Microtainer MAP tube enables automated processing with 81 percent less blood than venous systems, improving test turnaround time and laboratory efficiency. This is a critical improvement for patients from whom it is difficult to obtain a sufficient blood sample to perform critical diagnostic tests.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
For more information, visit www.bd.com .
BD Public Relations